Get Ready to Invest: BlockDAGs Presale Raises $10.5M and Attracts a Flock of Investors!

The frenzy surrounding BlockDAG (BDAG)’s presale has led investors to rapidly deplete its batches, raising an impressive $10.5 million across five rounds. This remarkable success highlights the immense confidence and anticipation surrounding BlockDAG, which is poised to reshape the blockchain landscape. Investors Flock To BlockDAG’s Presale Amidst this excitement, investors are flocking to BlockDAG’s presale…

Read More

Entero Therapeutics Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics Receives Notice of Non-Compliance from Nasdaq Overview Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, recently announced that it received a letter from the Nasdaq Stock Market stating that the company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to…

Read More

Unlock Your Trading Potential: Discover the Latest FX Option Expiries for 17 May at 10am New York Cut!

Unlock Your Trading Potential: Discover the Latest FX Option Expiries for 17 May at 10am New York Cut! Description: EUR/USD- 1.0795-10 (€751m)- 1.0825-35 (€556m)- 1.0915-20 (€619m) USD/JPY- 134.50 ($2.1bn)- 135.50 ($1.3bn)- 136.00-10 ($1.3bn)- 136.80 ($806m)- 137.00 ($503m) USD/CAD- 1.3400 ($1.2bn)- 1.3450 ($1.3bn) EUR/JPY- 141.00 (€1.0bn) There are a couple of big ones to take note…

Read More

Revolutionizing Cancer Treatment: The Incredible Power of Engeneics’ Nanocell Drug Conjugate for Pancreatic Cancer Patients

EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) — EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious journal “Clinical Cancer Research”, published by the American Association for Cancer Research….

Read More